Dengue Fever in Public Health
Clinical review
Keywords:
Review, Dengue, Public HealthAbstract
In Ecuador, borne disease dengue virus is a matter of great concern for public health and it is possible that the traditional government health efforts to reduce the problem are not being efficient. This makes it necessary to redirect these actions, which is consistent with the growing consensus that no single intervention is sufficient to control the disease. While even the existence of a vaccine is far away, in the light of what we know so far, it is possible that for a long time, you must continue to rely, even in an integrated manner, in vector control, epidemiological surveillance and the dynamic management of the disease burden. The work presented below is about the current way of addressing these actions and some experiences.
References
Murray NE, Quam MB, Wilder-Smith A. Epidemiology of dengue: past, present and future prospects. Clin Epidemiol. 2013;5:299-309. Published 2013 Aug 20. doi: 10.2147/CLEP.S34440.
World Health Organization. Global strategy for dengue prevention and control, 2012-2020. Geneva, Switzerland: World Health Organization; 2012. Disponible en: http://apps.who.int/iris/bitstream/10665/75303/1/9789241504034_eng.pdf.
Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW et al. (2013). The global distribution and burden of dengue, Nature 496: 504–507.
World Health Organization. World Malaria Report 2013. Geneva, Switzerland: World Health Organization; 2013. Disponible en: http://www.who.int/malaria/publications/world_malaria_report_2013/en/.
WHO. Report on strategic and technical meeting on intensified control of neglected tropical diseases. Geneva, Switzerland: World Health Organization; 2006. Disponible en: http://whqlibdoc.who.int/hq/2006/WHO_CDS_NTD_2006.1_eng.pdf.
Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet. 2012;380(9853):1559-1567. doi: 10.1016/S0140-6736(12)61428-7.
Erlanger TE, Keiser J, Utzinger J. Effect of dengue vector control interventions on entomological parameters in developing countries: a systematic review and meta-analysis. Med Vet Entomol. 2008;22(3):203-221. doi: 10.1111/j.1365-2915.2008.00740.x.
MSP. Indicadores Básicos de Salud. Quito, Ecuador: Ministerio de Salud Publica. 2008.
MSP. Boletín epidemiológico Dengue semana epidemiológica 39. Quito, Ecuador: Ministerio de Salud Pública. 2012.
MSP. Boletín epidemiológico Dengue semana epidemiológica 39. Quito, Ecuador: Ministerio de Salud Pública. 2013.
Lambrechts L, Scott TW, Gubler DJ. Consequences of the expanding global distribution of Aedes albopictus for dengue virus transmission. PLoS Negl Trop Dis. 2010;4(5):e646. doi:10.1371/journal.pntd.0000646.
OMS. Dengue guidelines for diagnosis, treatment, prevention and control. Geneva: World Health Organization; 2009.
Lyons AG. The human dengue challenge experience at the Walter Reed Army Institute of Research. J Infect Dis. 2014;209 Suppl 2:S49-S55. doi:10.1093/infdis/jiu174.
Monath TP. Yellow fever and dengue- the interactions of virus, vector and host in the re-emergence of epidemic disease. Sem Virol. 1994;5:133-45.
Ooi EE, Goh KT, Gubler DJ. Dengue prevention and 35 years of vector control in Singapore. Emerg Infect Dis. 2006;12(6):887-893. doi: 10.3201/10.3201/eid1206.051210.
Arias J. El dengue en Cuba. Revista Panamericana de Salud Pública. 2002;11(4):221–222.
Egger JR, Ooi EE, Kelly DW, Woolhouse ME, Davies CR, Coleman PG. Reconstructing historical changes in the force of infection of dengue fever in Singapore: implications for surveillance and control. Bull World Health Organ. 2008;86(3):187-196. doi: 10.2471/blt.07.040170.
Scott TW, Morrison AC. Vector dynamics and transmission of dengue virus: implications for dengue surveillance and prevention strategies: vector dynamics and dengue prevention. Curr Top Microbiol Immunol. 2010;338:115-128. doi: 10.1007/978-3-642-02215-9_9.
Stoddard ST, Wearing HJ, Reiner RC Jr, et al. Long-term and seasonal dynamics of dengue in Iquitos, Peru. PLoS Negl Trop Dis. 2014;8(7):e3003. doi: 10.1371/journal.pntd.0003003.
Gubler DJ. Dengue, Urbanization and Globalization: The Unholy Trinity of the 21(st) Century. Trop Med Health. 2011;39(4 Suppl):3-11. doi: 10.2149/tmh.2011-S05.
Lai S, Huang Z, Zhou H, et al. The changing epidemiology of dengue in China, 1990-2014: a descriptive analysis of 25 years of nationwide surveillance data. BMC Med. 2015;13:100. doi: 10.1186/s12916-015-0336-1.
Ooi EE. Surveillance for dengue. In: Gubler DJ, Ooi EE, Vasudevan SG, Farrar J, editors. Dengue and dengue hemorrhagic fever. Oxfordshire: CAB International; 2013: pp. 78–89.
Potts JA, Rothman AL. Clinical and laboratory features that distinguish dengue from other febrile illnesses in endemic populations. Trop Med Int Health. 2008;13(11):1328-1340. doi: 10.1111/j.1365-3156.2008.02151.x.
Scott TW, Takken W. Feeding strategies of anthropophilic mosquitoes result in increased risk of pathogen transmission. Trends Parasitol. 2012;28(3):114-121. doi: 10.1016/j.pt.2012.01.001.
Simmons CP, Farrar JJ, Nguyen vV, Wills B. Dengue. N Engl J Med. 2012;366(15):1423-1432. doi: 10.1056/NEJMra1110265.
Halstead SB. Dengue vaccine development: a 75% solution?. Lancet. 2012;380(9853):1535-1536. doi: 10.1016/S0140-6736(12)61510-4.
Rogers DJ, Wilson AJ, Hay SI, Graham AJ. The global distribution of yellow fever and dengue. Adv Parasitol. 2006;62:181-220. doi: 10.1016/S0065-308X(05)62006-4.
Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science. 1988;239(4839):476-481. doi: 10.1126/science.3277268.
Rodhain, F. La situation de la dengue dans le monde. Bull. Soc. Pathol. Exot. 1996;89:87–90
Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev. 1998;11(3):480-496.
Chakravarti A, Arora R, Luxemburger C. Fifty years of dengue in India. Trans R Soc Trop Med Hyg. 2012;106(5):273-282. doi: 10.1016/j.trstmh.2011.12.007.
Kakkar M. Dengue fever is massively under-reported in India, hampering our response. BMJ. 2012;345:e8574. Published 2012 Dec 19. doi: 10.1136/bmj.e8574.
Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 [published correction appears in Lancet. 2013 Feb 23;381(9867):628. AlMazroa, Mohammad A [added]; Memish, Ziad A [added]]. Lancet. 2012;380(9859):2197-2223. doi: 10.1016/S0140-6736(12)61689-4.
Johansson MA, Hombach J, Cummings DA. Models of the impact of dengue vaccines: a review of current research and potential approaches. Vaccine. 2011;29(35):5860-5868. doi: 10.1016/j.vaccine.2011.06.042.
Anders KL, Hay SI. Lessons from malaria control to help meet the rising challenge of dengue. Lancet Infect Dis. 2012;12(12):977-984. doi: 10.1016/S1473-3099(12)70246-3.
Cummings DA, Iamsirithaworn S, Lessler JT, et al. The impact of the demographic transition on dengue in Thailand: insights from a statistical analysis and mathematical modeling. PLoS Med. 2009;6(9):e1000139. doi: 10.1371/journal.pmed.1000139.
Jaenisch T; IDAMS, Sakuntabhai A; DENFREE, Wilder-Smith A; DengueTools. Dengue research funded by the European Commission-scientific strategies of three European dengue research consortia [published correction appears in PLoS Negl Trop Dis. 2014 Apr;8(4):e2883]. PLoS Negl Trop Dis. 2013;7(12):e2320. Published 2013 Dec 12. doi: 10.1371/journal.pntd.0002320.
OMS. International travel and health: situation as on 1 January 2012. Geneva, Switzerland: World Health Organization; 2012.
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Science Ecuador
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.
This is a human-readable summary of (and not a substitute for) the license.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
